| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Edoardo Spina, Concetta D'Arrigo, Gaetana Migliardi, Letterio Morgante, Rocco Zoccali, Maria Ancione, Aldo Madi. Plasma risperidone concentrations during combined treatment with sertraline. Therapeutic drug monitoring. vol 26. issue 4. 2004-12-20. PMID:15257068. |
the effect of sertraline on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-oh-risperidone) was studied in 11 patients with schizophrenia or schizoaffective disorder. |
2004-12-20 |
2023-08-12 |
human |
| Zhongyun Zha. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. Current medical research and opinion. vol 20. issue 7. 2004-12-10. PMID:15265249. |
economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. |
2004-12-10 |
2023-08-12 |
Not clear |
| Zhongyun Zha. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. Current medical research and opinion. vol 20. issue 7. 2004-12-10. PMID:15265249. |
this study, based upon a database analysis, compares a one-year drug treatment course (duration of therapy, concomitant use of typical antipsychotics, anxiolytics/antidepressants or anti-parkinsonians) and direct health care costs of uncontrolled schizophrenia patients initiated on olanzapine versus risperidone. |
2004-12-10 |
2023-08-12 |
Not clear |
| Nan Luo, Yvonne Koh, Chay Hoon Tan, Ee Heok Kua, Shu Chuen L. Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore. Human psychopharmacology. vol 19. issue 4. 2004-12-02. PMID:15181654. |
risperidone has been used in singapore for schizophrenia since 1996. |
2004-12-02 |
2023-08-12 |
Not clear |
| Yang-Tae Kim, Byung-Jo Kan. A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human psychopharmacology. vol 19. issue 4. 2004-12-02. PMID:15181655. |
a preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. |
2004-12-02 |
2023-08-12 |
human |
| Yang-Tae Kim, Byung-Jo Kan. A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human psychopharmacology. vol 19. issue 4. 2004-12-02. PMID:15181655. |
the aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia. |
2004-12-02 |
2023-08-12 |
human |
| Yang-Tae Kim, Byung-Jo Kan. A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human psychopharmacology. vol 19. issue 4. 2004-12-02. PMID:15181655. |
the subjects were schizophrenic outpatients, all meeting dsm-iv diagnostic criteria for schizophrenia and already treated with risperidone. |
2004-12-02 |
2023-08-12 |
human |
| T Dilla, L Prieto, A Ciudad, J A Sacristá. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder]. Actas espanolas de psiquiatria. vol 32. issue 5. 2004-12-02. PMID:15529211. |
this article reviews the complete pharmacoeconomic studies that compare olanzapine with haloperidol and risperidone in the treatment of schizophrenia. |
2004-12-02 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Yue-Cune Chang, Chih-Chiang Chiu, Sue-Hong Lee, Cher-Yeang Lin, Wen-Ho Chan. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. Psychopharmacology. vol 172. issue 4. 2004-11-29. PMID:14663551. |
fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. |
2004-11-29 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Yue-Cune Chang, Chih-Chiang Chiu, Sue-Hong Lee, Cher-Yeang Lin, Wen-Ho Chan. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. Psychopharmacology. vol 172. issue 4. 2004-11-29. PMID:14663551. |
risperidone doses for acute schizophrenia were rather high in most recent studies. |
2004-11-29 |
2023-08-12 |
Not clear |
| Zhiling Zhou, Xin Li, Kunyan Li, Zhihong Xie, Zeneng Cheng, Wenxin Peng, Feng Wang, Ronghua Zhu, Huande L. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 802. issue 2. 2004-11-29. PMID:15018785. |
clozapine (clz), olanzapine (olz), risperidone (rip) and quetiapine (qtp) have been widely used in the treatment of schizophrenia. |
2004-11-29 |
2023-08-12 |
Not clear |
| Montserrat Vera-Llonch, Thomas E Delea, Erin Richardson, Marcia Rupnow, Amy Grogg, Gerry Oste. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 7. issue 5. 2004-11-16. PMID:15367252. |
outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a markov model. |
2004-11-16 |
2023-08-12 |
Not clear |
| Montserrat Vera-Llonch, Thomas E Delea, Erin Richardson, Marcia Rupnow, Amy Grogg, Gerry Oste. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 7. issue 5. 2004-11-16. PMID:15367252. |
to compare expected outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders who are treated with risperidone versus olanzapine. |
2004-11-16 |
2023-08-12 |
Not clear |
| Mariëlle Eerdekens, Ilse Van Hove, Bart Remmerie, Erik Mannaer. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia research. vol 70. issue 1. 2004-11-02. PMID:15246468. |
pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. |
2004-11-02 |
2023-08-12 |
human |
| Mariëlle Eerdekens, Ilse Van Hove, Bart Remmerie, Erik Mannaer. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia research. vol 70. issue 1. 2004-11-02. PMID:15246468. |
the pharmacokinetics and tolerability of long-acting risperidone (risperdal consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia. |
2004-11-02 |
2023-08-12 |
human |
| Robert A Lasser, Cynthia A Bossie, Georges M Gharabawi, Martin Turne. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European psychiatry : the journal of the Association of European Psychiatrists. vol 19. issue 4. 2004-10-26. PMID:15196604. |
patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. |
2004-10-26 |
2023-08-12 |
Not clear |
| Jim van Os, Cynthia A Bossie, Robert A Lasse. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. International clinical psychopharmacology. vol 19. issue 4. 2004-10-26. PMID:15201570. |
in a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments. |
2004-10-26 |
2023-08-12 |
Not clear |
| Martin Turner, Els Eerdekens, Mary Jacko, Mariëlle Eerdeken. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International clinical psychopharmacology. vol 19. issue 4. 2004-10-26. PMID:15201572. |
long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. |
2004-10-26 |
2023-08-12 |
human |
| Martin Turner, Els Eerdekens, Mary Jacko, Mariëlle Eerdeken. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International clinical psychopharmacology. vol 19. issue 4. 2004-10-26. PMID:15201572. |
the results indicate that patients with schizophrenia who are symptomatically stable during treatment with a conventional depot antipsychotic can be safely and effectively switched to long-acting injectable risperidone without a prior transition to oral risperidone. |
2004-10-26 |
2023-08-12 |
human |
| G Zannino, A Gargiulo, F Lamenza, M G Marotta, T Barzotti, A Silvestri, E Ettorre, V Mariglian. The management of psychogeriatric patient. Archives of gerontology and geriatrics. Supplement. issue 9. 2004-10-21. PMID:15207448. |
risperidone and olanzapine are two atypical anti-psychotics, which already proved to be adequate and well tolerated during the treatment of schizophrenia and of acute maniacal disorders. |
2004-10-21 |
2023-08-12 |
Not clear |